Anlotinib Plus TQB2450 Combined With Nab-paclitaxel & Cisplatin as

Updated 04/26/2024

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05812430
Study type	Interventional
Source	The First Affiliated Hospital of Zhengzhou University
Contact	Hong Zong, doctor
Phone	0086-13523586882
Email	zonghong522@126.com
Status	Recruiting
Phase	Phase 2
Start date	April 10, 2023
Completion date	October 10, 2024

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05009953` - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05820906` - Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer	Phase 2
	Completed	`NCT03358849` - Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer	Phase 1
	Recruiting	`NCT05410197` - Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)	Phase 2
	Active, not recruiting	`NCT04727996` - Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05823987` - Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)	Phase 2
	Not yet recruiting	`NCT04733521` - A Phase 1/2 Study of SC-43 in Combination With Cisplatin	Phase 1/Phase 2
	Recruiting	`NCT04027764` - Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer	Phase 2
	Recruiting	`NCT05781074` - Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）	Phase 2
	Recruiting	`NCT04781192` - The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers	Phase 1/Phase 2
	Recruiting	`NCT05653180` - IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer	Phase 1/Phase 2
	Recruiting	`NCT04005339` - NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer	Phase 2
	Completed	`NCT04217954` - HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC	Phase 2
	Recruiting	`NCT05170438` - Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment	Phase 2
	Active, not recruiting	`NCT04172402` - NGS as the First-line Treatment in Advanced Biliary Tract Cancer	Phase 2
	Withdrawn	`NCT02597465` - A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507	Phase 3
	Active, not recruiting	`NCT04969887` - Combination Immunotherapy in Rare Cancers Under InvesTigation	Phase 2
	Recruiting	`NCT04211168` - Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers	Phase 2